DK2004688T3 - Forbedrede selektive protofibrille antistoffer og anvendelsen deraf - Google Patents

Forbedrede selektive protofibrille antistoffer og anvendelsen deraf

Info

Publication number: DK2004688T3
Authority: DK; Denmark
Prior art keywords: disease; protofibril; enhanced selective; binding; protofibril antibodies
Prior art date: 2006-03-23

Application number

DK07747965.7T

Other languages

English (en)

Other versions

DK2004688T4 (da

Inventor

Par Gellerfors

Lars Lannfelt

Dag Sehlin

Pettersson Frida Ekholm

Hillevi Englund

Original Assignee

Bioartic Neuroscience Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-23

Filing date

2007-03-23

Publication date

2011-03-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38522718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2004688(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-23 Application filed by Bioartic Neuroscience Ab filed Critical Bioartic Neuroscience Ab

2011-03-21 Publication of DK2004688T3 publication Critical patent/DK2004688T3/da

2014-05-12 Application granted granted Critical

2014-05-12 Publication of DK2004688T4 publication Critical patent/DK2004688T4/da

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)

DK07747965.7T 2006-03-23 2007-03-23 Forbedrede selektive protofibrille antistoffer og anvendelsen deraf DK2004688T4 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE0600662		2006-03-23
SE0602591		2006-11-30
PCT/SE2007/000292 WO2007108756A1 (en)	2006-03-23	2007-03-23	Improved protofibril selective antibodies and the use thereof

Publications (2)

Publication Number	Publication Date
DK2004688T3 true DK2004688T3 (da)	2011-03-21
DK2004688T4 DK2004688T4 (da)	2014-05-12

Family

ID=38522718

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07747965.7T DK2004688T4 (da)	2006-03-23	2007-03-23	Forbedrede selektive protofibrille antistoffer og anvendelsen deraf

Country Status (28)

Country	Link
US (2)	US8025878B2 (da)
EP (2)	EP2325209A3 (da)
JP (1)	JP5033868B2 (da)
KR (1)	KR101413615B1 (da)
CN (1)	CN101421303B (da)
AT (1)	ATE492561T1 (da)
AU (1)	AU2007227813B9 (da)
BR (1)	BRPI0709050B1 (da)
CA (1)	CA2630344C (da)
CY (1)	CY1111337T1 (da)
DE (1)	DE602007011415D1 (da)
DK (1)	DK2004688T4 (da)
FI (1)	FIC20250030I1 (da)
FR (1)	FR25C1034I1 (da)
HR (1)	HRP20110203T4 (da)
HU (1)	HUS2500037I1 (da)
IL (1)	IL191331A (da)
MX (1)	MX2008012223A (da)
MY (1)	MY169492A (da)
NL (1)	NL301343I2 (da)
NO (2)	NO347079B1 (da)
NZ (1)	NZ567888A (da)
PL (1)	PL2004688T5 (da)
RS (1)	RS51723B2 (da)
RU (1)	RU2429244C2 (da)
SI (1)	SI2004688T2 (da)
WO (1)	WO2007108756A1 (da)
ZA (1)	ZA200805805B (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001268005A1 (en)	2000-07-07	2002-01-21	Lars Lannfelt	Prevention and treatment of alzheimer's disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
SG10201706600VA (en)	2005-11-30	2017-09-28	Abbvie Inc	Monoclonal antibodies and uses thereof
KR20080090408A (ko)	2005-11-30	2008-10-08	아보트 러보러터리즈	항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
BRPI0709050B1 (pt)	2006-03-23	2018-12-26	Bioarctic Neuroscience Ab	anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
DK2006381T3 (da)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til regulering af antistoffers blodfarmakokinetik
PE20080333A1 (es)	2006-06-08	2008-06-15	Chugai Pharmaceutical Co Ltd	Agentes para prevenir o tratar enfermedades inflamatorias
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2008204335B2 (en)	2007-01-11	2013-06-13	Michael Bacher	Diagnosis and treatment of Alzheimer's and other neurodementing diseases
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
DK2202245T3 (da)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til modificering af et antistofs isoelektriske punkt via aminosyresubstitution i cdr
ES2687808T3 (es)	2007-09-26	2018-10-29	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
CA2701793C (en)	2007-10-05	2017-04-25	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
ME01026B (me) *	2007-11-16	2012-10-20	Univ Rockefeller	Antitijela specifična za protofibrilni oblik beta-amiloid proteina
MX337081B (es) *	2007-12-05	2016-02-10	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-nr10 y su uso.
CA2714413C (en) *	2008-02-08	2017-01-24	Immunas Pharma, Inc.	Antibody capable of binding specifically to ab-oligomer, and use thereof
JP5747414B2 (ja)	2008-04-29	2015-07-15	バイオアークティックニューロサイエンスアーベー	α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
US9085614B2 (en) *	2008-08-01	2015-07-21	Immunas Pharma, Inc.	Antibodies that specifically bind to Aβ oligomers and uses thereof
ES2533493T3 (es) *	2008-08-20	2015-04-10	Probiodrug Ag	Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
TWI646193B (zh)	2009-03-19	2019-01-01	中外製藥股份有限公司	抗體恆定區域改變體
JP5812418B2 (ja)	2009-04-17	2015-11-11	イムナス・ファーマ株式会社	Ａβオリゴマーに特異的に結合する抗体およびその利用
FR2945538B1 (fr)	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
PT2448968T (pt) *	2009-06-29	2021-04-30	Bioarctic Ab	ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
EP2273273A1 (en) *	2009-07-11	2011-01-12	Rheinische Friedrich-Wilhelms-Universität Bonn	Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
ES2614949T3 (es) *	2009-08-06	2017-06-02	Immunas Pharma, Inc.	Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
JP5769316B2 (ja)	2009-08-06	2015-08-26	イムナス・ファーマ株式会社	Ａβオリゴマーに特異的に結合する抗体およびその利用
US10266585B2 (en)	2009-08-28	2019-04-23	The Board Of Regents Of The Univerity Of Texas System	Methods of treating brain injury
WO2011063523A1 (en) *	2009-11-24	2011-06-03	Alethia Biotherapeutics Inc.	Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
JP5894939B2 (ja)	2010-02-26	2016-03-30	バイオアークティックニューロサイエンスアーベー	プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
EP2576617B1 (en)	2010-06-04	2016-04-27	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin	MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
CN103179981B (zh) *	2010-07-30	2017-02-08	Ac免疫有限公司	安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en)	2010-08-14	2015-06-23	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
CA2817973C (en) *	2010-10-15	2019-06-25	The Board Of Regents Of The University Of Texas System	Antibodies that bind amyloid oligomers
DK2663579T3 (da)	2011-01-14	2017-07-31	Univ California	Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse deraf
EP2497782A1 (en)	2011-03-08	2012-09-12	Alzinova AB	Anti oligomer antibodies and uses thereof
SG11201401360XA (en)	2011-10-25	2014-05-29	Onclave Therapeutics Ltd	Antibody formulations and methods
JP2013159596A (ja) *	2012-02-08	2013-08-19	Nihon Univ	β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
CA2862739A1 (en)	2012-02-22	2013-08-29	Alethia Biotherapeutics Inc.	Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
KR102321320B1 (ko)	2013-07-09	2021-11-03	애넥슨, 인코포레이티드	항-보체 인자 ｃ１ｑ 항체 및 이의 용도
ES2792183T3 (es)	2013-09-13	2020-11-10	Beigene Switzerland Gmbh	Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CA2924268C (en) *	2013-11-21	2021-05-18	F. Hoffmann-La Roche Ag	Anti-alpha-synuclein antibodies and methods of use
CN106604742B (zh)	2014-07-03	2019-01-11	百济神州有限公司	抗pd-l1抗体及其作为治疗剂及诊断剂的用途
SI3166970T1 (sl) *	2014-07-10	2021-09-30	Bioarctic Ab	Izboljšana A-beta protofibril vezavna protitelesa
SG11201700496WA (en)	2014-07-22	2017-02-27	Cb Therapeutics Inc	Anti-pd-1 antibodies
SG10201901057UA (en)	2014-08-05	2019-03-28	Cb Therapeutics Inc	Anti-pd-l1 antibodies
US10316081B2 (en)	2014-11-05	2019-06-11	Annexon, Inc.	Humanized anti-complement factor C1Q antibodies
WO2016100615A2 (en) *	2014-12-18	2016-06-23	The University Of Chicago	Methods and composition for neutralization of influenza
ES3036076T3 (en)	2015-04-14	2025-09-12	Chugai Pharmaceutical Co Ltd	Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2016167263A1 (ja)	2015-04-14	2016-10-20	中外製薬株式会社	Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US11327080B2 (en)	2015-07-21	2022-05-10	BioArctic Neruoscience AB	Method for treatment of traumatic brain injury targeting aggregated peptides
BR112018010360A2 (en)	2015-11-24	2018-12-04	Annexon, Inc.	anti-c1q complement factor fab fragments and uses thereof
JP2017132742A (ja) *	2016-01-29	2017-08-03	国立大学法人大分大学	Ａβオリゴマー特異的抗体の新規薬理用途
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
CN109475536B (zh)	2016-07-05	2022-05-27	百济神州有限公司	用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
AU2017297804A1 (en)	2016-07-14	2019-01-24	Bioarctic Ab	Brain delivery protein
PT3500299T (pt)	2016-08-19	2024-02-21	Beigene Switzerland Gmbh	Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
US20200055917A1 (en)	2016-09-27	2020-02-20	Cero Therapeutics, Inc.	Chimeric engulfment receptor molecules
IL316169A (en)	2016-10-27	2024-12-01	Eisai R&D Man Co Ltd	Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
CN110461847B (zh)	2017-01-25	2022-06-07	百济神州有限公司	(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
TW202515616A (zh)	2017-06-26	2025-04-16	英屬開曼群島商百濟神州有限公司	抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
US11530257B2 (en) *	2017-06-29	2022-12-20	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
AU2018308088B2 (en)	2017-07-25	2025-05-29	Truebinding, Inc.	Treating cancer by blocking the interaction of TIM-3 and its ligand
US11382974B2 (en)	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
FI3688032T3 (fi)	2017-09-26	2025-12-09	Cero Therapeutics Holdings Inc	Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä
WO2019108795A1 (en)	2017-11-29	2019-06-06	Beigene Switzerland Gmbh	Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
EP3753952A4 (en) *	2017-12-13	2022-04-13	XDCExplorer (Shanghai) Co., Ltd.	EGFRVIII ANTIBODY AND CONJUGATE, AND METHODS FOR ITS PRODUCTION AND USE
WO2019191332A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
AU2019243154A1 (en)	2018-03-28	2020-10-01	Cero Therapeutics, Inc.	Cellular immunotherapy compositions and uses thereof
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
US12325741B2 (en)	2018-07-17	2025-06-10	Jiangsu Hengrui Medicine Co., Ltd.	Anti-Aβ antibodies and antigen-binding fragments thereof
CA3107370A1 (en) *	2018-07-24	2020-01-30	Eisai R&D Management Co., Ltd.	Methods of treatment and prevention of alzheimer's disease
BR112022006590A2 (pt)	2019-11-20	2022-06-28	Chugai Pharmaceutical Co Ltd	Preparação contendo anticorpos
EP4097136A4 (en) *	2020-01-29	2024-07-31	The Trustees of The University of Pennsylvania	Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
US12281166B2 (en)	2020-05-26	2025-04-22	Truebinding, Inc.	Methods of treating inflammatory diseases by blocking Galectin-3
FI4172199T3 (fi)	2020-06-26	2025-08-12	Bioarctic Ab	Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet
EP4264277A4 (en) *	2020-12-16	2024-12-11	Cognext Diagnostics LLC	Methods for diagnosing alzheimer's disease and other neurological disorders
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
US20240141027A1 (en)	2021-06-11	2024-05-02	Bioarctic Ab	Bispecific binding molecule
WO2023283650A1 (en)	2021-07-09	2023-01-12	Eisai R&D Management Co., Ltd.	Biomarkers for alzheimer's disease treatment
WO2023034230A1 (en)	2021-08-30	2023-03-09	Eisai R&D Mangement Co., Ltd.	Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
CA3239708A1 (en)	2021-12-03	2023-06-08	Aubin MICHALON	Novel potency assay for antibody-based drugs and useful means therefor
US12486322B2 (en)	2021-12-13	2025-12-02	Annexon, Inc.	Anti-complement factor C1q antibodies with single binding arms and uses thereof
US20250051427A1 (en)	2021-12-17	2025-02-13	Eisai R&D Management Co., Ltd.	Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023111618A1 (en)	2021-12-17	2023-06-22	Eisai R&D Management Co., Ltd.	Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko)	2022-02-02	2024-09-30	에자이 알앤드디 매니지먼트 가부시키가이샤	P-tau181 수준을 사용한 치료 방법
WO2024118665A1 (en)	2022-11-28	2024-06-06	Eisai R&D Management Co., Ltd.	Methods of treatment using a tau pet level
WO2024155876A1 (en)	2023-01-20	2024-07-25	Mabwell Therapeutics, Inc.	ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF
TW202513583A (zh)	2023-06-09	2025-04-01	日商衛材R&D企管股份有限公司	使用抗Ａβ初原纖維抗體之治療方法
WO2025122968A1 (en)	2023-12-06	2025-06-12	Eisai R&D Management Co., Ltd.	Predicting mild cognitive impairment based on patient co-morbidities
WO2025137532A1 (en) *	2023-12-21	2025-06-26	Eisai R&D Management Co., Ltd.	Method for quantifying amyloid beta protofibril

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231000A (en)	1987-10-08	1993-07-27	The Mclean Hospital	Antibodies to A4 amyloid peptide
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US6174916B1 (en)	1990-04-27	2001-01-16	Milkhaus Laboratory, Ltd.	Methods for treating herpes virus infections
JP2980677B2 (ja)	1990-04-27	1999-11-22	マクマイケル，ジョン	不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
DE69426571T2 (de)	1993-10-27	2001-08-09	Elan Pharm Inc	TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
JP3064013B2 (ja)	1994-05-25	2000-07-12	ジョンマクマイケル，	斑形成疾患の治療のための方法及び材料
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en)	1994-11-14	2008-09-23	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
US5817626A (en)	1995-03-14	1998-10-06	Praecis Pharmaceuticals Incorporated	Modulators of beta-amyloid peptide aggregation
US5854215A (en)	1995-03-14	1998-12-29	Praecis Pharmaceuticals Incorporated	Modulators of β-amyloid peptide aggregation
US6303567B1 (en)	1995-03-14	2001-10-16	Praecis Pharmaceuticals, Inc .	Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2214247C (en)	1995-03-14	2004-02-10	Praecis Pharmaceuticals Incorporated	Modulators of amyloid aggregation
US5985242A (en)	1995-10-27	1999-11-16	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
WO1997041856A1 (en)	1996-05-08	1997-11-13	Massachusetts Institute Of Technology	ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
US20030068316A1 (en)	1997-02-05	2003-04-10	Klein William L.	Anti-ADDL antibodies and uses thereof
US6218506B1 (en)	1997-02-05	2001-04-17	Northwestern University	Amyloid β protein (globular assembly and uses thereof)
US20060178302A1 (en)	1997-02-05	2006-08-10	Northwestern University & The University Of Southern California	Amyloid beta protein (globular assembly and uses thereof)
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE1033998T1 (de)	1997-12-03	2001-05-23	Brigham And Women's Hospital, Boston	Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
AU2486900A (en)	1998-12-29	2000-07-31	University Of Georgia Research Foundation, Inc., The	Rubredoxin fusion proteins, protein expression system and methods
WO2000071671A2 (en)	1999-05-26	2000-11-30	New York University	New mutant genes in familial british dementia and familial danish dementia
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
AR024558A1 (es)	1999-06-01	2002-10-16	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
EP1571158B1 (en)	1999-08-04	2009-10-14	University Of Southern California	Globular assembly of amyloid beta protein and uses thereof
AU784312B2 (en)	1999-11-29	2006-03-09	Bellus Health (International) Limited	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU7487301A (en)	2000-05-22	2001-12-03	Univ New York	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
AU2001268005A1 (en) *	2000-07-07	2002-01-21	Lars Lannfelt	Prevention and treatment of alzheimer's disease
US20030187011A1 (en)	2001-12-20	2003-10-02	Lashuel Hilal A.	Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
WO2003068801A2 (en) *	2002-02-11	2003-08-21	Genentech, Inc.	Antibody variants with faster antigen association rates
NZ536064A (en)	2002-04-19	2008-06-30	Univ Toronto	Immunological methods and compositions for the treatment of alzheimer's disease
JP2003334075A (ja) *	2002-05-21	2003-11-25	Japan Tobacco Inc	簡便な変異抗体の製造方法
US20040049134A1 (en)	2002-07-02	2004-03-11	Tosaya Carol A.	System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
EP1578361B1 (en) *	2002-09-12	2011-04-20	The Regents of The University of California	Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
AU2003279728B2 (en)	2002-10-01	2007-09-27	Northwestern University	Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
AU2003285151A1 (en)	2002-11-04	2004-06-07	Bioarctic Neuroscience Ab	Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005011599A2 (en)	2003-08-01	2005-02-10	Northwestern University	Antibodies specific for toxic amyloid beta protein oligomers
WO2005019828A1 (en)	2003-08-20	2005-03-03	Amorfix Life Sciences Ltd.	Epitope protection assay and method for detecting protein conformations
JP2007527865A (ja)	2003-09-12	2007-10-04	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
SE0400707D0 (sv)	2004-03-22	2004-03-22	Bioarctic Neuroscience Ab	Transgenic animal model
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
AU2005269940A1 (en)	2004-07-02	2006-02-09	Northwestern University	Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta)
US20060079447A1 (en)	2004-10-08	2006-04-13	Wetzel Ronald B	Stabilized A-beta protofibrillar aggregates
US20080044356A1 (en)	2004-10-22	2008-02-21	Regents Of The University Of Minnesota	Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006055178A2 (en)	2004-10-25	2006-05-26	Merck & Co., Inc.	Anti-addl antibodies and uses thereof
WO2006066233A1 (en) *	2004-12-15	2006-06-22	Neuralab Limited	An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
WO2006083533A2 (en)	2005-01-14	2006-08-10	The Regents Of The University Of California	Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
US7731962B2 (en)	2005-02-14	2010-06-08	Merck & Co., Inc.	Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en)	2005-02-14	2010-04-20	Merck & Co., Inc.	Non-immunostimulatory antibody and compositions containing the same
KR20080021585A (ko)	2005-03-05	2008-03-07	애보트 게엠베하 운트 콤파니 카게	스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
US7741448B2 (en)	2005-06-21	2010-06-22	Medical & Biological Laboratories Co., Ltd.	Antibody having inhibitory effect on amyloid fibril formation
TW200726774A (en)	2005-06-30	2007-07-16	Merck & Co Inc	Composition and method for producing stable amyloid beta oligomers
TW200726482A (en)	2005-06-30	2007-07-16	Merck & Co Inc	Method for preparing a covalently cross linked oligomer of amyloid beta peptides
EP1940466B1 (en)	2005-10-21	2012-11-28	Merck Sharp & Dohme Corp.	Anti-addl monoclonal antibodies and use thereof
US9133267B2 (en)	2005-11-22	2015-09-15	The Trustees Of The University Of Pennsylvania	Antibody treatment of Alzheimer's and related diseases
BRPI0709050B1 (pt)	2006-03-23	2018-12-26	Bioarctic Neuroscience Ab	anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
ME01026B (me)	2007-11-16	2012-10-20	Univ Rockefeller	Antitijela specifična za protofibrilni oblik beta-amiloid proteina
PT2448968T (pt)	2009-06-29	2021-04-30	Bioarctic Ab	ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

2007
- 2007-03-23 BR BRPI0709050A patent/BRPI0709050B1/pt not_active IP Right Cessation
- 2007-03-23 NO NO20084445A patent/NO347079B1/no unknown
- 2007-03-23 CN CN2007800098173A patent/CN101421303B/zh active Active
- 2007-03-23 AU AU2007227813A patent/AU2007227813B9/en active Active
- 2007-03-23 WO PCT/SE2007/000292 patent/WO2007108756A1/en not_active Ceased
- 2007-03-23 MY MYPI20083703A patent/MY169492A/en unknown
- 2007-03-23 US US12/294,207 patent/US8025878B2/en active Active
- 2007-03-23 SI SI200730510T patent/SI2004688T2/sl unknown
- 2007-03-23 DE DE602007011415T patent/DE602007011415D1/de active Active
- 2007-03-23 HR HRP20110203TT patent/HRP20110203T4/hr unknown
- 2007-03-23 EP EP10195985A patent/EP2325209A3/en not_active Withdrawn
- 2007-03-23 NZ NZ567888A patent/NZ567888A/en unknown
- 2007-03-23 JP JP2009501383A patent/JP5033868B2/ja active Active
- 2007-03-23 DK DK07747965.7T patent/DK2004688T4/da active
- 2007-03-23 CA CA2630344A patent/CA2630344C/en active Active
- 2007-03-23 KR KR1020087023261A patent/KR101413615B1/ko active Active
- 2007-03-23 PL PL07747965T patent/PL2004688T5/pl unknown
- 2007-03-23 RU RU2008141905/10A patent/RU2429244C2/ru active
- 2007-03-23 MX MX2008012223A patent/MX2008012223A/es active IP Right Grant
- 2007-03-23 AT AT07747965T patent/ATE492561T1/de active
- 2007-03-23 EP EP07747965.7A patent/EP2004688B2/en active Active
- 2007-03-23 RS RS20110122A patent/RS51723B2/sr unknown
2008
- 2008-05-11 IL IL191331A patent/IL191331A/en active IP Right Grant
- 2008-07-02 ZA ZA2008/05805A patent/ZA200805805B/en unknown
2011
- 2011-03-15 CY CY20111100288T patent/CY1111337T1/el unknown
- 2011-08-26 US US13/219,012 patent/US9034334B2/en active Active
2025
- 2025-08-29 FI FIC20250030C patent/FIC20250030I1/fi unknown
- 2025-09-03 FR FR25C1034C patent/FR25C1034I1/fr active Active
- 2025-09-05 NO NO2025041C patent/NO2025041I1/no unknown
- 2025-09-09 HU HUS2500037C patent/HUS2500037I1/hu unknown
- 2025-09-12 NL NL301343C patent/NL301343I2/nl unknown

Also Published As

Publication number	Publication date
RU2429244C2 (ru)	2011-09-20
KR20080106288A (ko)	2008-12-04
AU2007227813B2 (en)	2012-09-27
EP2004688A1 (en)	2008-12-24
ZA200805805B (en)	2010-09-29
EP2325209A2 (en)	2011-05-25
BRPI0709050A2 (pt)	2011-06-21
NO20084445L (no)	2008-10-22
JP5033868B2 (ja)	2012-09-26
MX2008012223A (es)	2008-12-17
NZ567888A (en)	2010-08-27
NO2025041I1 (no)	2025-09-05
AU2007227813A1 (en)	2007-09-27
SI2004688T1 (sl)	2011-03-31
ATE492561T1 (de)	2011-01-15
AU2007227813B9 (en)	2025-11-20
BRPI0709050B1 (pt)	2018-12-26
IL191331A (en)	2015-07-30
CN101421303A (zh)	2009-04-29
US8025878B2 (en)	2011-09-27
KR101413615B9 (ko)	2024-12-18
NO347079B1 (no)	2023-05-08
EP2004688B1 (en)	2010-12-22
PL2004688T3 (pl)	2011-06-30
RS51723B2 (sr)	2018-03-30
CA2630344C (en)	2015-04-28
CY1111337T1 (el)	2015-08-05
EP2004688B8 (en)	2011-03-02
US20120076726A1 (en)	2012-03-29
US9034334B2 (en)	2015-05-19
DE602007011415D1 (de)	2011-02-03
HK1120056A1 (en)	2009-03-20
FIC20250030I1 (fi)	2025-08-29
CA2630344A1 (en)	2007-09-27
HRP20110203T4 (hr)	2014-05-09
EP2004688B2 (en)	2014-03-05
JP2009530374A (ja)	2009-08-27
FR25C1034I1 (fr)	2025-11-21
MY169492A (en)	2019-04-15
SI2004688T2 (sl)	2014-05-30
KR101413615B1 (ko)	2014-07-18
RU2008141905A (ru)	2010-04-27
RS51723B (sr)	2011-10-31
DK2004688T4 (da)	2014-05-12
HUS2500037I1 (hu)	2025-09-28
PL2004688T5 (pl)	2014-09-30
CN101421303B (zh)	2013-06-12
HRP20110203T1 (en)	2011-04-30
WO2007108756A1 (en)	2007-09-27
EP2325209A3 (en)	2011-08-03
US20090258009A1 (en)	2009-10-15
NL301343I2 (nl)	2025-10-02

Publication	Publication Date	Title
DK2004688T3 (da)	2011-03-21	Forbedrede selektive protofibrille antistoffer og anvendelsen deraf
MX2022005782A (es)	2022-08-16	Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
WO2006121852A3 (en)	2007-02-08	Anti-cd19 antibody therapy for autoimmune disease
UA109633C2 (uk)	2015-09-25	Антитіло людини проти тканинного фактора
WO2008067464A3 (en)	2008-12-04	NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES
NO20090156L (no)	2009-03-27	Humanisert antistoff
ATE435239T1 (de)	2009-07-15	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
WO2006089133A3 (en)	2006-12-21	Anti-cd19 antibodies and uses in oncology
WO2008060364A3 (en)	2009-02-19	Humani zed antibody against amyloid beta
MX2009013503A (es)	2010-01-27	Anticuerpo monoclonal anti-amiloide-beta.
WO2007047112A3 (en)	2007-08-16	Anti-myostatin antibodies
EA200702053A1 (ru)	2008-02-28	Антитела против cd38 для лечения множественной миеломы
GB0603683D0 (en)	2006-04-05	Organic compounds
IL193444A (en)	2015-10-29	Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
PH12011502389A1 (en)	2016-01-11	Monoclonal antibody
CO6280540A2 (es)	2011-05-20	Proteinas de union a beta-amiloide que comprenden anticuerpos, fragmentos de anticuerpos y otras construcciones de proteinas
EA200801343A1 (ru)	2008-12-30	Иммуноглобулины, направленные против nogo
CY1114604T1 (el)	2016-10-05	Ανθρωποποιημενο αντισωμα εναντιον αμυλοειδους βητα
CL2023000099A1 (es)	2023-08-11	Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular
IL185653A0 (en)	2008-01-06	Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
SG162829A1 (en)	2010-07-29	Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
TW200740845A (en)	2007-11-01	Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
CY1115021T1 (el)	2016-12-14	Μονοκλωνικα αντισωματα εναντι αμυλοειδους βητα πρωτεϊνης και χρησεις αυτων
CY1116887T1 (el)	2017-04-05	Anti-cd19 αντισωματα και χρησεις στην ογκολογια
EA202190387A1 (ru)	2022-01-31	Антитело к cd38 человека и его применение